Trial Profile
68Ga-DOTATATE PET-CTA Imaging for the Early Detection of Progressing Coronary Atherosclerosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs Gallium 68-DOTATATE (Primary)
- Indications Atherosclerosis; Coronary arteriosclerosis
- Focus Diagnostic use
- Acronyms IPROGRESS
- 29 Jun 2022 Status changed from active, no longer recruiting to discontinued.
- 15 Oct 2021 Status changed from not yet recruiting to active, no longer recruiting.
- 14 Dec 2018 New trial record